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- 
The endathellumdepndent wedilator wbslanee P dilates aar. 
mat ai4 diseased coronary vessels in humans in vivn and produres 
a maxima: respow rtmitar 10 ,hn, r:n wi,h intnroronary 
ircaarbick dinitmtr. Twtve cardiac bsnsplant tipimn under- 
wnl Intmacoron~ry intush of subrlsnre P *er murim annual 
investig&ms. All patimb were well, with no evidence olrejeetion 
and with nwl~raohtlv normal eorrmarv arleries. Substance P _ 
was lnihsed at 2 mUmin tar 2 min in6 the eoronary ar@ry. 
stwtln~ a, a dose of 1.4 pmoVmin ilnZ increasing by doubting 
imcmminb, and f&wed by tamorhide dini,rs,e t, mpimin~ 
infuvd over 2 min. Connnry artery diameter wu measured in 23 
vwsel sqments irom I2 transplant recipientx 
The f&wing doses were lafarrd: satire $olalion tl mUminI. 
suhstatw P (0.7 [three patienlal, 1.4. 2.8, 5.6. 11.2, 22.4 pmoli 
The most imponan, deterroinan, oflong-term prognosi\ after 
cardiac transplanralion is ,he development of accelera,cd 
coronary artery disease (II. The normal physiologic hehav- 
ior of the coronary arteries may he altered after cardiac 
transplantation. as a result of weral possible mechant\m\ 
including denervation (2) and injury 10 the endolhelium by 
the cardioplegic solution during the period of ischemic wrest 
(3). In addition. immunologically medialed inJury 10 the 
eodorhelium 14) may occur and this process of enddhelial 
damage has been postulated to he involved in the develop 
rnentif accelerated coronary artery disease. 
Endothelial celk have been shown to he ohlixaiory tn the 
relaxation of smooth muscle by acctylcholme 6 and in vwo 
intracoronaiy studies have been carried oo, urinp ,tu* agent. 
It has bfsn demonstrated (6) that in disease ~tateb wch as 
atherosclerosis there is pandoxic mrocon~lriction in re- 
sponse to acetylcholine. whereas normal coronary YC~FCIF 
respond with dilation. suggesling Ihat there may he endothe- 
2.9%. 16.5 t 2.6%. 19.2 * 3.1% and 25.8 i 2.28. mpertivel~. 
Halt maximal dilation was produced with 1.4 to 2.8 pmoVmtn of 
substance p: ltte maxtmat response tnean percent diameter 
ehanact was 22 f 2.5%. Thir was net Figiacantty di&en, from 
that achieved si,h .sororbidc dinitraa. 
It is eanclurkd ,ha, ewonary end&&at funrtion as aamed 
by reqw~re ,U subsbmce P is preserred in wrdiac transplant 
recipienk with aqiographically normal coronary arterie% Sub 
stance P may he a suitable ageat for ,estingendo,heliat fonefian in 
these patients. 
that dy\funci’on in patients w,h nlherowlerosls. In cardiac 
,ronspkm, reopicnts. similar rludieg 11) uamg inlracoronary 
acetylchohne have suggested ,hat there may be endolhelial 
d)$f,tnct,on in the coronary arteries with graft sclero%. 
Other invr\,l$awrs (81 have shown a vasoconnric,or re- 
sponse to ~ramcoronary acetylcholine early after cardiac 
,r.msolanlahon and have suestioned the link between the 
;&choline response and endotbelial dyrfunction in grafl 
coronarv scleros,~. In vi,ro investications 19) of isolated 
coronary arteries have also shown iha, acetylcholine may 
not always relax these ve?lseIs and. when infused directly. 
may CB,I% vasoconstr~c~ton m viva in ,he mqority of caws 
(IQ). 
S~:hrrewe P is wt I I a,nino arid vnsodilntor ~nrropep- 
ride. II IS found in the peripheral nervow system in sensory 
neuron\ II It, the vagos (12) and some sympathetic gangba 
(13). It has also been localized to the prrivarcular nerves of 
many animals (141 and the petivawlar regions of small 
artermtes I” the human hean (IS). It is a potent varodilaror 
in humane. causing vaboddadon in rhe forcarm when infused 
m,o rhe brachial artery ,161 and dilating epicardial coronary 
arterie* when infused into Ihe coronary circulation 117). 
The vasodilative action of substance P has been shown 
to he cndothelium dependent in mob, species (1% including 
humans llY.?O). and its action in human coronary anery 
rings IF abolished by the nitric oxide synlhcsis inhibitor 
L-P:i’~n~,~,au,~ielhyi.~r~~nlnc l?II. Thw studies thereiule in. 
dicaie ~hal auh\lance Pi\ a polenl Gmulanl ofendolhehum- 
derived relaxing fdclor producrion by endolhelium. The aim 
of this slody WI\ 10 investigdtc the use of,uhslance P in Ihe 
waluation of coronary endolhelial function m palien!, with 
angiographically nwmal coronary art&\ after cardiac 
trdn\planlal!on. 
Methods 
Study patients (Table II. Twelve men were wdied I 10 5 
years (~%n 35 months) after cardiac ~ransplanlalion. The 
mean age WBS 53 years (range 47 to 631. All wientb had 
angiographically normal coronary arleries. which was the 
only %lcction crilenon: lhey were no! preselecled. At the 
time of muline annual investigauon. all were clinically well. 
with no evidence of cardiac rejection a> assessed by endo- 
myocardial biopsy. Table I li$t\ the clinical characteristics VI 
the I? petienls and includes patient and donor age. the time 
after transplxdalion at which Ihe wdy was carried out. the 
number of treated rejection episodes and the ischemic time5 
of the donor heart. 
Infusion protocol. Substance P infuuaion was carried out 
after righ! hear1 c;,!hetcriration. left venhculography. selec- 
tive coronary angiogrdphy and right venlricular endomyo- 
cardial hiopry. Coronary ar:criugraphy was petiirmed with 
the Judkim technique. A baseline ang~ogram performed with 
Omnipaque 350 liohcxoll was obtained in the projection best 
displaying the coronary anatomy. as determined previously 
from the dmgnosric films. Thor powion was noI altered 
throughout the course of the study. A high rebolution 
12.7 cm image inlenGficr (Optimur M?W Philhps) wa\ used. 
After a conlrol an&ram was obtained. saline solution wab 
Gused 81 I ml/mm for 2 min. This vehicle infusion was 
carried out before the infusion of wbalance P in all I2 
patients. Increasing concentrations of substance P were then 
infurrd 01 a slartinp dose of 0.7 pmollmin in three patients 
and of I .4 pmolimin in nine pal&. Immediately after the 
infusion. another coronary angiogram was performed. A 
dose of aub\tance P twice as large as the previous dose was 
then infused at the same infusion rate. Angiograms were 
repeated and thi? procedure was continued to a maximal 
dose of 22.4 pmol!min in 10 patients and of Il.2 pmollmin in 
2 padems. On completion of the subslance P infusions. 
isororhidc dinitrate wes infused at I mgimin for 2 min. when 
a final sngiogram was taken. In II of the I2 patients. 
wbstance P was infused into the I& coronary artery and in 
I paGem it was infused into Ihe right coronary anery. 
Ethics. Informed written consenl was obtained from each 
palient. The study was approved by the Ethical Committee 
of Harefield Hospital and the Research and Ethical Commit- 
tea of Hammeramith Hospital. 
Quantitative angiographic analysis. Coronary artery lumi- 
nal diameter was measured by an aulomated edge detection 
computer analysis syster (Cardiovascular Angiography 
An&is System. CAAS. Pie Data Medical). End-diastolic 
film frames were used for analysis and specific proximal 
se.wnem~ of Ihe left anterior descending and circumflex 
&onary arterie were chosen. A point after the first diago- 
nal branch of the left anterior descendmg anery and after the 
firs! obtuse marginal brdnch ofrhe lefi circumflex artery was 
used and the diameter across this point was measured. The 
size of the corooary catheter (7F in all cares) was used for 
calibration of the image in millimelers and correction was 
made for mdiogrdphicwpincushion distortion. In all. 23 cor- 
onary vessel segments were analyzed: I I left anterior de- 
scending artery regmen& i I left circumflex artery ,rgments 
and I right coronary a:vy segment in Ihc p+cpl lrhn hali 
tbc right coroxr; :n?rg infuua~on). Six of ihe I? film\ were 
reanalyzed by a second observer and the rnea,urement aa\ 
hghly reproducible (r = 0.983. p = NS between ub~rra- 
[ions) 
Data presentation. Coronary dmmcier IS exprewd in 
millimeters 01 as percent diamex; chan:c from the conwol 
value. Mean v&es 2 I SEW are given for each dose ot 
subslanc~ P. Responses were compared by using rcpcatcd 
meas”remcnfs analysis of variance A p value a.05 Will 
taken to indicate r;gnificance. 
Results 
The infusion studies were well toluxcd by all palients. 
wilb no adverse effects durw~ wbsrance P or iwrbidc 
dinitrate infusion. No patient expenenced symptonn during 
any suge of the infusions. No alteranon m the wface 
el&trocardiogram was seen. 
Epicardial dilarion (Zahle 2). The miual infusIon of 0.9% 
N saline solution caused no significant change in corowry 
diameter compared with that dacrmined v:/:b !be b~~~bne 
vehicle infusion. Substance P caused a dose-depadent 
increase in proximal luminal diameter (Fig. Il. In I5 wsei 
segments. the maximal recponse occurred at the two maw 
mal doses of substance P, but in the remaining 8 segments 
rhe maximal response occurred at lower dozes oi 2.8 and 
5.6 pmolimin; half maximal dilanon uas produced *ith I .4 10 
2.0 pmollmin. The mean maximal percent dilatmn achieved 
with substance P was not significantly different from that 
achieved with isosorbide dinitralc (22.02 r 2.16% VI. 
25.76 3- 2.17%) (Fig. I). The mean preinfurion diameter was 
2.98 + 0.12 mm. For the total group, there was a swuficant 
difference between baseline vehicle infusion. lower doxs of 
subsrance P and the II.2 and 22.1 pmollmm doses of 
substance P. Analy& of individcal patient maximal re- 
sponse to substance P and isosorbide dirdrratc. howPer. 
showed that there were six vase! segment% in six padents 
whose maximal substance P nponse was attenuated m 
comparison with the response to isorblde dwtrale (Rg. 2). 
Peripheral homodynamic eUecls. There vu no sigmficanr 
change in heart rate with increasing doses of suhwnce P and 
isosorbide dinitrate. Femoral arwy sy~olic prer~re 
showed a tendency to decrease B, higher doso of wb<tance 
P (bat reached significanct ar the IL? and z_ 4 pmollmin 
level (Q i 0.055) compared with the lower dew (Fig. 31. The 
mean maximal decrease m systolic pressure was II.25 mm 
Hg. There was no furlher r~gnificant decrcasc in aoruc 
systolic pressure after infusion of lsorblde dinilrate. There 
was a similar trend for aortic dnrtobc pre~ure. with a 
significant di&rence berween the 2 8 pmollmin dobe and the 
two maximal doses I I I 2 and 22 4 pmolimin) of substance P 
obrened in large cpxardial vec~els is similar in degree to the 
va\oddaw observed in nomml pauent~ after infusion of 
~nua~oronary substance P and amte~ (I?). Furthermore. in 
our pauen,<. there wils no relaimn between the lcn@h of 
time after cardmc rransplanta~ion a d the degree of re%Fonsc 
10 substance P. suggesting lhal the coronary endothebum 
rem&m\ a physiologically a&c organ many years aflcr 
Ir:intnl:l”l:llInn 
Comparison 4th other studier. A recent in vitro study 
(21) of human epicardial coronary rings indicated that rclan- 
ation induced b> substance P i$ mediated bv endolhelium- 
dewed relaun;factor because relaxalion aicc:on:;) rings 
wa mhihilcd bv L-N”-monamefhvl-arciinine IL-NMSlAI. _ 
ahlch is a ipccifk inhihilor of mm oxtde formation from 31s 
precursor L-arginine. Nnnc onde is now thoughr lo be 
mdothclium-derived relaxing faclor I??). These observa- 
hens zugge\i that the vasodilation observed in respon~r ID 
substance P m our palicnts is due to the release of endothe- 
bum-dcrwed relaxing factor. In rwtrast. it was previouslr 
wggeslcd (71 that endorhelisi dysfunction. 10 a degree rhat 
wggests a lack of cndothebum-derived relaxing factor re- 
ICBIC. 15 an early finding after cardiac transplar.tation as 
<how” in rtudies with intracoronary acetylcholine. Acefyl- 
cbobne has heen demonswaled 10 be a dilator of coionarj 
arteries in vwo and m vitro in the presence of an intacl 
cndothelium. However. different studies (7.8) of Ihe re- 
sponse of co:onary arteries m cardiac transplant recipients 
10 intracoronq acetylcholine have rho?‘% vwine results. 
Fish et 81. (71 demonstrated rhat in tbc czajority of patient% 
wrh anpiorraphically smooth coronary arleries. the arlene~ 
faled to dilate or displayed paradoxic vasoconril&xl in 
rewonse 10 acetvlcholine. II was implied that endothelial 
d);func:ion war. prewnt and that lherc 1s some causal 
rclai~on m the devrlopmem of coronary aherosderosa in 
Ihex patients. More r&ntly. ii was tbown (231 that ace~yl- 
choline mav have a much greater riTect an coronary blood 
flow than on epicardial coro&ry dwmeter and that it tends 10 
C~UIC coronary vasoconstriction in the mawily of patienls. 
even those with normal coronary a:Wies. A!!hough studies 
in vilro (9.19) and tn viva (6) have demonstrated a dilative Ip < 0.0%. The mean maximal dccree\e m aort~c dlaslobc 
pressure. 5.63 mm Hg. occurred al 22.4 pmollmin. Aonac responss of epicardial coronary artcries IO acetylchobnc. 
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It is probable that the overall elfect of acetylcholine 
depends on the mterplny hitwcrn direct xwconwiction 
and endothelium-derived rclavng factor-medived vosodila- 
tton. In vie\” of the widely differmg findings obtained from 
ddi’crenl groups, it appexs lbat acstylcholine IS not a spe- 
clfic agent for testing endothelial function. Our Pndmgs 
auggw th;d wbstance P may be a more specific marker of 
endothelium-dependent vasodilalion. which produces a 
grriacr magnitude ofdilation than that achieved wilh acetyl- 
choline. 
Physiologic role of substance P. Substance P IS a neu- 
ropeptidc and immunoreacwily has been demonstrated in 
the human heart (15). Althuugh 16 specific role has yet to be 
identified. wbsmnce P may play a part in the neural regula- 
tion of coronary artery tone. Long-term studies after human 
cardiac fransplan~~~:or suggest hat the donor heart remains 
function.& (241 and alatomicaily (i5i denervated. We have 
shown that substance P causes vawdilation in the dener- 
vated heart similar 10 lhal demonstrated m patients with 
normally mnervaled hearts and no evidence-of coronary 
artery disease (17). Denervation. therefore. does not appear 
to cause significant changes in substance P receptorfunc- 
tion, unlike the denervation hypersensitivity demonstrated 
in response 10 sympathomimetic amines in the transplanted 
human heart (26) and in canine preparawns (27). In this 
rcspcct, these resulls complement the observalions of others 
(28) using animal preparations that hypersensitivity does not 
occur with other neuropeptides such as calcitonin gene- 
related peptide. Receptors for suhstancc P have been dem- 
onstrated by autoradiographic analysis ofthe endothelium of 
the dog carotid (291 and renal (30) artery and human coro- 
Figure 2. Maximal response (expressed as percem increase in
diameter) to intracoronary substance P in 23 vc~sel segments 
compared wlh the response 10 intracomnary !rosorbide dinilrale 
IISDN, in Ihe same “else, segmentr. 
nary arlery (Dashwood MR, personal communication). A 
recent study (31) demonstrated thal substance P is released 
from the rat hind limb vasculawre under conditions of 
increased blood Row before and after pharmacologic dener- 
vation. suggesting that the source of substance P might be 
the endothelium itself; it was further observed that release of 
substance P was abolished after removal of endothelium. 
These studies. in addition to our own findings. suggest that 
substance P is active mainlv at the endolhelial level and its 
aclion is not affected by d&ervation despite its demonstra- 
tion in neural tissue (I I-13). 
Relevance of vasedilator esponse. The response to sub- 
stance P in the presence of atherosclerosis has been 
demonstrated to be preserved in some patients but not 
in others (32). implying that even in the presence of athero. 
sclerosis, there may be enough functional endolhelium to 
mediate a vasodilator response. II is therefore possible 
that lack of response to substance P may only be a marker 
of severe endothelial damage. Bosealler et al. (19). how- 
ever, showed in isolated preparations of human coronary 
arteries that the response to substance Pin the presence of 
alherosclerosis is diminished. It is therefore difficult to 
spcculale whelher the finding of reduced response to sub. 
stance P in comparison with that to isosorbide dinitrate in 
Correlation with clinical factors. There was nu rrlatinn 
between the magnitude of dilrlor response IO rubslmce P 
with other factors. such as lime after lranrplanrarion. donor 
age, ischemic time of the donor heart and numhcr of rejec- 
Lion episodes. Tao pntv%ls (Patients 4 and I I1 had Marc 
hn four episodes of rcjeciion early in their postqxr&e 
course. One of these patients IPatient 41 had a markedly 
reduced response 10 substance P. but rhe other (Parienr I I) 
had a very powerful vasodilaror response. It 5eem\ unlikely 
that there is an assocralion bctwccn prcviou, qecrion 
episodes and s&stance P response. It is no, clear, houcrcr. 
what the response would be during the active phase of 
rejection. 
Comparison with isororbide dinitrate reqxxe. Allhouph 
there was some individual variability in the maCnal re- 
sponse to substance P. the mean response Was nor slgnifi- 
cantly different from that to isosorbide dinitmte. In most of 
the vessels sluched. subhtance P achieved mar;mxal or near 
maximal dilation compared with isosorbide dinilrate. In only 
two of the vessel segments studied ~85 the response to 
isosorbide dinitrate substanMy greater than that oblained 
with substance P. tn those patients uho did not respond well 
to either iiosorbide dinitrate or subslance P. il IS likely that 
there is limitation ofvasorelaxarion. which may in parr reYull 
from the state of denervation 12). 
Conch&m. In cardiac transplant recipients. coru~ry 
endothelial function is preserved. as demonsrrared by a 
preserved relaxant response m inrracoronary substance P. 
In patients wilh no evidence of acceleralcd coronary 
artery disease, the degree of response is not affected 
by the time after transplantation. suggesting that the 
endolhelium remains a functionallv active oman in thex 
patients. Substance P appears to be a useful pharmacologic 
agent for the invest&lion of endothelial function and ill 
active in very small amounts. Further invesligations are 
necessary to determine endothelial function in those patients 
who have already developed coronary artery disease LO 
examine lhe role that endothelium plays in ihe dircasc 
process. 
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